Wednesday, April 3, 2013

IQWIG - Eliquis has significant additional benefit over Warfarin

According to benefit assessment conducted by IQWIG,  Eliquis (apixaban, Bristol-Myers Squibb / Pfizer) has in certain patients with atrial fibrillation, a significant additional benefit over existing therapies.
In patients over 65 and eligible for treatment with warfarin,  Eliquis offer significant addition benefit compared to warfarin. Also in patients not eligible for treatment with warfarin who are currently treated with aspirin, Eliquis offers benefit when compared to aspirin. Eliquis cuts  the risk of  stroke or major bleeding.
 


Enter your email address:


Delivered by FeedBurner